Key Highlights
- Nuvation Bio sold $287.5 million of 0.75% convertible senior notes, including a full $37.5 million greenshoe.
- Net proceeds are projected at $277.6 million after underwriting costs, with $2.2 million allocated to capped‑call transactions.
- Notes bear 0.75% interest, mature July 1 2032, and can convert if the Class A stock exceeds 130% of the conversion price.
Nuvation Bio Inc. (NYSE: NUVB) closed a registered underwritten public offering that generated $287.5 million in gross proceeds.
Offering Overview
The closing on June 30 2026 marked the issuance of $250.0 million of notes carrying a 0.75% coupon. Under the underwriting agreement dated June 25, the syndicate was granted a thirty‑day right to acquire additional notes up to $37.5 million, a right they exercised in its entirety on July 6 2026.
Greenshoe Execution
The supplemental $37.5 million of notes mirrors the terms of the original issuance, bringing the total principal sold to $287.5 million. This full greenshoe increased the size of the financing while keeping the original interest rate and maturity timetable intact.
Use of Proceeds
Nuvation Bio anticipates receiving roughly $277.6 million after deducting underwriting discounts and other offering expenses. Approximately $2.2 million of that amount will be used to fund capped‑call agreements that aim to limit dilution, with the balance allocated to general corporate purposes such as working capital and capital expenditures.
Note Terms
The unsecured notes accrue interest at 0.75% per annum, with payments made twice a year. The first interest payment is scheduled for January 1, 2027, and subsequent payments occur on each July 1 thereafter. The notes mature on July 1 2032 unless they are converted, redeemed, or repurchased earlier.
Conversion Mechanics
Investors may elect to convert the notes into Class A common stock before April 1 2032 if the market price of the stock exceeds 130% of the conversion price for a minimum of five trading days within a specified observation window. After April 1 2032, conversion is allowed at any time up to the second business day before maturity, regardless of the stock price.
Capped Call Hedging
On July 1 2026, Nuvation Bio entered into capped‑call contracts with an affiliate of one of the underwriters and other financial institutions. These agreements cap the conversion price at $10.4580 per share, which reflects an 80.0% premium over the Class A stock price observed on June 25 2026, thereby reducing potential dilution for existing shareholders.
Regulatory Filing
The securities were issued pursuant to a Form S‑3 registration filing identified by file number 333‑285621, which was dated March 6 2025. The offering was conducted under the Securities Act of 1933, with a prospectus supplement released on June 25 2026.
Market Context
Biotech companies increasingly turn to convertible senior notes as a flexible financing tool, allowing them to secure capital at relatively low interest rates while offering investors the upside of equity conversion. Nuvation Bio’s use of a greenshoe and capped‑call structure aligns with industry practices designed to manage dilution risk and preserve cash for R&D initiatives. This financing positions the company to continue advancing its pipeline amid a competitive landscape where access to capital remains critical for growth.
FAQs
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...